JP2023519962A5 - - Google Patents

Info

Publication number
JP2023519962A5
JP2023519962A5 JP2022559492A JP2022559492A JP2023519962A5 JP 2023519962 A5 JP2023519962 A5 JP 2023519962A5 JP 2022559492 A JP2022559492 A JP 2022559492A JP 2022559492 A JP2022559492 A JP 2022559492A JP 2023519962 A5 JP2023519962 A5 JP 2023519962A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
sequence numbers
mertk
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022559492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024970 external-priority patent/WO2021202590A1/en
Publication of JP2023519962A publication Critical patent/JP2023519962A/ja
Publication of JP2023519962A5 publication Critical patent/JP2023519962A5/ja
Withdrawn legal-status Critical Current

Links

JP2022559492A 2020-03-31 2021-03-30 抗mertk抗体及びその使用方法 Withdrawn JP2023519962A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003070P 2020-03-31 2020-03-31
US63/003,070 2020-03-31
US202163165592P 2021-03-24 2021-03-24
US63/165,592 2021-03-24
PCT/US2021/024970 WO2021202590A1 (en) 2020-03-31 2021-03-30 Anti-mertk antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023519962A JP2023519962A (ja) 2023-05-15
JP2023519962A5 true JP2023519962A5 (enExample) 2024-04-10

Family

ID=75625652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559492A Withdrawn JP2023519962A (ja) 2020-03-31 2021-03-30 抗mertk抗体及びその使用方法

Country Status (5)

Country Link
US (1) US20240294650A1 (enExample)
EP (1) EP4126937A1 (enExample)
JP (1) JP2023519962A (enExample)
CN (1) CN116075525A (enExample)
WO (1) WO2021202590A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
MX2021010003A (es) 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
CA3156803A1 (en) 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MX2022007231A (es) 2019-12-13 2022-07-12 Alector Llc Anticuerpos anti-mertk y metodos de uso de los mismos.
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CA3217372A1 (en) * 2021-05-14 2022-11-17 Masoud TAVAZOIE Mertk peptides and uses thereof
EP4423142A4 (en) * 2021-10-27 2025-10-22 Atyr Pharma Inc COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2A ANTIBODIES
CN121889428A (zh) * 2023-09-25 2026-04-17 安斯泰来制药株式会社 抗MerTK激动剂抗体、抗MerTK双特异性抗体及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US10123621B2 (en) * 2015-11-19 2018-11-13 The Lovesac Company Furniture system recliner assembly with sled rails
WO2019084307A1 (en) 2017-10-26 2019-05-02 Celldex Therapeutics, Inc. ANTI-MERTK ANTIBODIES AND METHODS OF USE
US20210188973A1 (en) * 2017-11-30 2021-06-24 University Of Tsukuba Activity Modulator
JP2022512642A (ja) * 2018-10-09 2022-02-07 ブリストル-マイヤーズ スクイブ カンパニー がんを治療するための抗MerTK抗体
WO2020106461A2 (en) 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
CN109678959B (zh) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 抗cd40抗体及其应用
MX2021010003A (es) * 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
BR112021020867A2 (pt) * 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração

Similar Documents

Publication Publication Date Title
JP2023519962A5 (enExample)
JP7781859B2 (ja) 抗ror1抗体及び関連の二重特異性結合タンパク質
CN110156892B (zh) 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
JP2023506465A5 (enExample)
CN104936981B (zh) Il‑17a结合物及其用途
JP2022524588A5 (enExample)
JP2014509861A5 (enExample)
JP2018510636A5 (enExample)
JP2022533538A5 (enExample)
CA3236138A1 (en) Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
JP2013535970A5 (enExample)
US11261246B2 (en) Anti-IL-22R antibodies
JP2021534797A5 (enExample)
JP2019516392A5 (enExample)
JP2024541680A5 (enExample)
JP2024001073A5 (enExample)
JP2025505650A5 (enExample)
JP2023531230A5 (enExample)
JP2019518473A5 (enExample)
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
US20250075000A1 (en) Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
US20260015430A1 (en) Antigen binding protein specific for transmembrane activator and caml interactor (taci)
RU2021112131A (ru) Антитела, нацеленные на epn1
WO2025024780A1 (en) Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途